newsfilter
← Latest News
Business Wire·

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced